Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.04.027 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Callie Berkowitz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Ca…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Factor VIII. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Novo Nordisk Haemophilia Foundation, Novo Nordisk.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA.
- Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA. Electr…
Förderung
- Novo Nordisk Haemophilia Foundation
- Novo Nordisk
Zitieren
APA
Berkowitz, C., Wilson, S., Key, N. S., & Ellsworth, P. (2024). Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.04.027
Vancouver
Berkowitz C, Wilson S, Key NS, Ellsworth P. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.04.027
BibTeX
@article{Berkowitz2024,
author = {Berkowitz, Callie and Wilson, Samuel and Key, Nigel S and Ellsworth, Patrick},
title = {Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.04.027}
}
EUVIMED